Skip to market wire
InvestLog
← Back to Stock Events← 返回个股快讯
ABTRegulatory Decision监管决定Primary source一手来源Source link原始来源by InvestLog AIInvestLog AI 整理
Event time: 事件时间：
Published: 文章发布：

ABT receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart conditionAbbott Laboratories（ABT）的 new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition 获美国 FDA 批准

ABT receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition.

Abbott Laboratories（ABT）的 new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition 获美国 FDA 批准。

View ABT stock details ->查看 ABT 个股详情 ->

For information only. Not investment advice.内容仅供参考，不构成投资建议。

Related articles相关阅读

Barclays initiates coverage of ABT with OverweightBarclays 首次覆盖 雅培 (ABT)，初始评级 增持（Overweight）

Rating Change · October 6, 2026评级变动 · 2026/10/6

ABT receives FDA approval for TactiFlex™ Duo Ablation CatheterAbbott Laboratories（ABT）的 TactiFlex™ Duo 消融导管 获美国 FDA 批准

Material Company Event · September 8, 2026公司公告 · 2026/9/8

Ford Robert B sells $46.2M of ABTFord Robert B 内部减持 雅培 (ABT) $46.2M

Insider Sale · August 27, 2026内部人减持 · 2026/8/27